Literature DB >> 17932503

Serum/glucocorticoid-induced protein kinase-1 facilitates androgen receptor-dependent cell survival.

I Shanmugam1, G Cheng, P F Terranova, J B Thrasher, C P Thomas, B Li.   

Abstract

Androgen receptor (AR) is a critical factor in the development and progression of prostate cancer. We and others recently demonstrated that eliminating AR expression leads to apoptotic cell death in AR-positive prostate cancer cells. To understand the mechanisms of AR-dependent survival, we performed a genome-wide search for AR-regulated survival genes. We found that serum/glucocorticoid-induced protein kinase-1 (SGK-1) mRNA levels were significantly upregulated after androgen stimulation, which was confirmed to be AR dependent. Promoter analysis revealed that the AR interacted with the proximal and distal regions of the sgk1 promoter, leading to sgk-1 promoter activation after androgen stimulation. Functional assays demonstrated that SGK-1 was indispensable for the protective effect of androgens on cell death induced by serum starvation. SGK-1 overexpression not only rescued cells from AR small-interfering RNA (siRNA)-induced apoptosis, but also enhanced AR transactivation, even in the absence of androgen. Additionally, SGK-1 siRNA reduced AR transactivation, indicating a positive feedback effect of SGK-1 expression on AR-mediated gene expression and cellular survival. Taken together, our data suggest that SGK-1 is an androgen-regulated gene that plays a pivotal role in AR-dependent survival and gene expression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17932503     DOI: 10.1038/sj.cdd.4402227

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  29 in total

1.  Development of a small-molecule serum- and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic.

Authors:  Andrea B Sherk; Daniel E Frigo; Christine G Schnackenberg; Jeffrey D Bray; Nicholas J Laping; Walter Trizna; Marlys Hammond; Jaclyn R Patterson; Scott K Thompson; Dmitri Kazmin; John D Norris; Donald P McDonnell
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

2.  Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers.

Authors:  Russell Z Szmulewitz; Elizabeth Chung; Hikmat Al-Ahmadie; Silver Daniel; Masha Kocherginsky; Aria Razmaria; Gregory P Zagaja; Charles B Brendler; Walter M Stadler; Suzanne D Conzen
Journal:  Prostate       Date:  2011-05-11       Impact factor: 4.104

3.  Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma.

Authors:  Yoshitsugu Mitani; Sue-Hwa Lin; Kristen B Pytynia; Renata Ferrarotto; Adel K El-Naggar
Journal:  Clin Cancer Res       Date:  2019-11-26       Impact factor: 12.531

Review 4.  AR-dependent phosphorylation and phospho-proteome targets in prostate cancer.

Authors:  Varadha Balaji Venkadakrishnan; Salma Ben-Salem; Hannelore V Heemers
Journal:  Endocr Relat Cancer       Date:  2020-06       Impact factor: 5.678

5.  Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.

Authors:  Masis Isikbay; Kristen Otto; Steven Kregel; Jacob Kach; Yi Cai; Donald J Vander Griend; Suzanne D Conzen; Russell Z Szmulewitz
Journal:  Horm Cancer       Date:  2014-03-11       Impact factor: 3.869

6.  Inhibition of SGK1 enhances mAR-induced apoptosis in MCF-7 breast cancer cells.

Authors:  Guilai Liu; Sabina Honisch; Guoxing Liu; Sebastian Schmidt; Stavros Pantelakos; Saad Alkahtani; Mahmoud Toulany; Florian Lang; Christos Stournaras
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 7.  PI-3 kinase p110β: a therapeutic target in advanced prostate cancers.

Authors:  Benyi Li; Aijing Sun; Wencong Jiang; J Brantley Thrasher; Paul Terranova
Journal:  Am J Clin Exp Urol       Date:  2014-10-02

8.  SGK3 is an estrogen-inducible kinase promoting estrogen-mediated survival of breast cancer cells.

Authors:  Yuanzhong Wang; Dujin Zhou; Sheryl Phung; Selma Masri; David Smith; Shiuan Chen
Journal:  Mol Endocrinol       Date:  2010-11-17

Review 9.  Targeting SGK1 in diabetes.

Authors:  Florian Lang; Agnes Görlach; Volker Vallon
Journal:  Expert Opin Ther Targets       Date:  2009-11       Impact factor: 6.902

Review 10.  Enhancing mTOR-targeted cancer therapy.

Authors:  Xuerong Wang; Shi-Yong Sun
Journal:  Expert Opin Ther Targets       Date:  2009-10       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.